Abstract
BackgroundChronic lymphocytic leukemia (CLL) is a mature lymphoid neoplasm currently categorized as an indolent type of malignant lymphoma. CLL progresses slowly over years, but it eventually transforms to a more aggressive lymphoma such as the diffuse large B-cell (DLBCL) type, also known as Richter’s syndrome.Case presentationWe treated a 69-year-old Japanese male who was histologically diagnosed with Richter’s syndrome after 6 years of CLL. His lymphadenopathy had systemically progressed for years, with lymphocyte counts of less than 10,000 cells/μL and a disease status of Rai classification stage I and Binet classification B. He had high fever and hepatosplenomegaly upon Richter’s transformation. The patient was treated with ofatumumab for refractory CLL, which relieved his febrile lymphadenopathy. He received a total of 11 ofatumumab courses and achieved partial remission. On the day of the 12th course of ofatumumab, his disease relapsed with febrile lymphadenopathy. Computed tomography revealed multiple liver masses and systemic lymphadenopathy, while a liver biopsy confirmed T-cell lymphoma. Concomitantly, CD20-lacking CLL cells were detected in his peripheral blood and bone marrow, and pathological examination of his left cervical lymph node biopsy showed CD20-positive DLBCL. The final diagnosis was three different types of lymphoma pathologies: (1) CD20-positive DLBCL of the lymph nodes, (2) CD20-lacking CLL of the peripheral blood and bone marrow, and (3) peripheral T-cell lymphoma (PTCL) of the liver. He received intravenous and oral dexamethasone therapy as palliative care. He died because of the rapid progression of abdominal masses 2 months after the diagnosis of triple transformation CLL. An autopsy revealed aggressive PTCL with aggressive systemic involvement of the liver, spleen, gall bladder, pericardium, bone marrow, and mediastinal–paraaortic–intraceliac lymph nodes. T-cell receptor study of an autopsy specimen supported the diagnosis of PTCL that spread to the intraceliac organs and lymph nodes. We concluded that his pathogenicity progressed to a mixture of triple lymphoma as a result of double malignant transformations, which included PTCL from CLL, CD20-negative CLL, and CD20-positive DLBCL by Richter’s transformation.ConclusionsOur case provides information on the biology of CLL, to transform from a low-grade chemosensitive status to a malignant chemoresistant status.
Highlights
Chronic lymphocytic leukemia (CLL) is a mature lymphoid neoplasm currently categorized as an indolent type of malignant lymphoma
There have been numerous reports describing the transformation of B-CLL to diffuse large B-cell lymphoma (DLBCL), the transformation to T-CLL and T-prolymphocytic leukemia has been rarely reported [3, 4]
We encountered a case of transformation of B-CLL to DLBCL followed by peripheral T-cell lymphoma (PTCL)
Summary
Richter’s syndrome is defined as the development of high-grade lymphoma in patients with chronic lymphocytic leukemia (CLL), previously diagnosed as small lymphocytic lymphoma [1, 2]. He sometimes received oral cyclophosphamide and prednisolone for better control of lymphocytosis (lymphocyte count > 10,000 cells/μL) His lymphadenopathy systemically progressed over the course of several years and mainly included bilateral cervical, intra-abdominal, paraaortic, and bilateral femoral lesions. He remained treatment-free with a clinical status of Rai classification stage I and Binet classification B. Upon reaching the age of 69 years, his CLL transformed into aggressive lymphoma, which was histologically diagnosed as DLBCL in his cervical lymph node His clinical presentation during the transformation revealed leukocytosis, hepatosplenomegaly, and high fever with chills. CD20-lacking CLL cells were confirmed in his peripheral blood and bone marrow by flow cytometry His left cervical pathological diagnosis remained as CD20-positive DLBCL. No clonal cytogenetic abnormalities were found in the three types of transformed clones described above (i.e., CD20-positive DLBCL, CD20-lacking CLL, and PTCL cells)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
